Unate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeted Antidrug Conjugate IPH4502 in Selected Advanced Solid Tumors

• IPH4502 is a novel and differentiated topoisomerase I inhibitor conjugated to exatecan targeting nectin-4

Marseille, France-(BUSINESS WIRE)–Regulatory news:

Innate farm SA (OTC 🙂 ( Euronext (EPA:) Paris: IPH; Nasdaq: ipha) (Congenital or Society) today announced that the first patient has been dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative antibody-drug conjugate (ADC), in patients with advanced solid tumors known to express nectin-4.

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including urothelial carcinoma (UC), breast carcinoma, non-small cell carcinoma, or gastrointestinal cancer. IPH4502 targets tumors with a wide range of Nectin-4 expression, supporting its development beyond UC. IPH4502 Differentiated topoisomerase I payload inhibitor supports its potential in patients with MMAE-ADC resistant tumors.

The Phase 1, open-label, multi-center study, including a Part 1 dose escalation and Part 2 dose optimization, will evaluate the safety, tolerability and preliminary efficacy of IPH4502 as a single agent in Nectin-4-expressing advanced solid tumors, including , but not limited to urothelial carcinoma, non-cellular lung, breast, ovarian, gastric, esophageal and colorectal carcinoma. The study plans to enroll about 105 patients.

We are delighted to have initiated a Phase 1 study of IPH4502, a promising therapy for patients with advanced solid tumors known to express nectin-4, said Dr. Shiraj Sen, Medical (TASE 🙂 Oncologist and Phase 1 Investigator, Director of Clinical Research, Next Oncology-dallas. IPH4502 is uniquely designed to target tumors with high and low nectin-4 expression, offering hope for improved outcomes in a population where effective treatment options are limited and relapses occur frequently. This study represents an important step forward in advancing innovative care for these patients.

The initiation of this Phase 1 trial represents a significant milestone for Innate Pharma (EPA 🙂 as our clinical phase pipeline now includes targeted ADCs. We are optimistic about the potential of IPH4502 to address an unmet need in the treatment of advanced solid tumors, with well-differentiated targeting of Nectin-4 and the promise of ADC technology to provide a new therapeutic option for patients,, added Dr Sonia Quaratino, Chief Medical Officer at Innate Pharma.

More information about the trial can be found at ClinicalTrials.gov.

About IPH4502

IPH4502 is a novel topoisomerase I inhibitor anti-drug conjugate (ADC) conjugated to exatecan targeting nectin-4. It is currently being investigated in a phase 1 trial in advanced solid tumors expressing nectin-4.

Nectin-4 is a cell adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic carcinomas, with limited expression in normal tissues.

In non-clinical models, IPH45 is well tolerated and exhibits antitumor activity in vitro and in vivo.

About innate pharmacy

Innate Pharma SA is a global clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK cell engagers via its proprietary ANKET ® platform (NK therapeutics for NK engagement) and antibody drug conjugates (ADCs) and monoclonal antibodies ( MABS).

Innate’s portfolio includes several anti-ANKET ® drug candidates to address multiple tumor types, as well as IPH4502, a differentiated ADC in solid tumor development. In addition, the anti-kir3dl2 mAb lacutamab was developed in advanced cutaneous T cell lymphomas and peripheral T cell lymphomas, and the anti-NKG2A mAb monalizumab was developed with AstraZeneca (NASDAQ 🙂 in squamous cell carcinoma.

Udate Pharma is a reliable partner to biopharmaceutical companies such as Sanofi (NASDAQ 🙂 and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Based in Marseille, France with a US office in Rockville, Ph.D. Med., Urođen Pharma is listed on Euronext Paris and Nasdaq in the USA.

Learn more about innate pharma at www.innate-pharma.com. Follow us further LinkedIn and X.

Innate Pharmacist Stock Information

Information and Risk Factor Disclaimer

This press release contains certain statements, including those within the meaning of applicable securities laws, including the Private Securities Reform Act of 1995. The use of certain words, including predict, believe, may, may, estimate, expect, may, Mogment, potential, expect, will, or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those projected. These risks and uncertainties include, among others, uncertainties inherent in research and development, including related to safety, progress and results from its ongoing and planned clinical trials and preclinical studies, regulatory review and approval of its product candidates, the Company’s reliance on third parties parties to manufacture its product candidates, the company’s commercialization and the company’s continued ability to raise capital to finance its development. For an additional discussion of the risks and uncertainties, which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, see the Risk Factors section (“Facteurs de Risque”) of the Universal Registration Document filed with the French of the financial market (AMF), which is available on the AMF website http://www.amf-france.org or on the Incane Pharma website, and public filings and reports filed by US securities and exchanges filed by US Securities and Exchange Commission (SEC), including the Company’s annual report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or the SEC or otherwise made public at AMF’s website is included for information only, and the content contained therein, or accessible through it, is not incorporated by reference and does not constitute a part of this release.

In light of the significant uncertainties in these forward-looking statements, you should not consider these statements to be a representation or warranty by the company or any other person that the company will achieve its goals and plans within any particular time frame or at all. The Company undertakes no obligation to publicly update any statements in the future, whether as a result of new information, future events or otherwise, except as required by law.

This release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy or subscribe for shares in Innate Pharmaceuticals in any country.

See the original version on BusinessWire.com: https://www.businesswire.com/news/home/20250126316836/en/

For additional information, please contact:

Investors

Innate farm
Henry Wheeler
Tel.: +33 (0) 4 84 90 32 88
Henry.wheeler@innate-pharma.fr

Relations with the media

New cap
Arthur Rouille
Tel.: +33 (0) 1 44 71 00 15 15
to anate@newcap.eu

Source: native Pharma SA